Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
serotonin–norepinephrine reuptake inhibitor |
| gptkbp:approvedBy |
gptkb:Europe
gptkb:Japan gptkb:United_States |
| gptkbp:ATCCode |
N06AX17
|
| gptkbp:brand |
gptkb:Savella
gptkb:Ixel Toledomin |
| gptkbp:CASNumber |
910482-45-6
|
| gptkbp:chemicalFormula |
C15H22N2O.ClH
|
| gptkbp:contraindication |
uncontrolled narrow-angle glaucoma
concurrent MAOI use |
| gptkbp:developedBy |
Pierre Fabre Medicament
|
| gptkbp:drugClass |
antidepressant
|
| gptkbp:eliminationHalfLife |
8 hours
|
| gptkbp:excretion |
urine
|
| https://www.w3.org/2000/01/rdf-schema#label |
milnacipran hydrochloride
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits reuptake of serotonin and norepinephrine
|
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
282.81 g/mol
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
constipation headache insomnia increased sweating |
| gptkbp:usedFor |
gptkb:major_depressive_disorder
fibromyalgia |
| gptkbp:bfsParent |
gptkb:Savella
|
| gptkbp:bfsLayer |
8
|